EP2494955B1 - Stable liquid pharmaceutical composition based on trazodone - Google Patents

Stable liquid pharmaceutical composition based on trazodone Download PDF

Info

Publication number
EP2494955B1
EP2494955B1 EP12170235.1A EP12170235A EP2494955B1 EP 2494955 B1 EP2494955 B1 EP 2494955B1 EP 12170235 A EP12170235 A EP 12170235A EP 2494955 B1 EP2494955 B1 EP 2494955B1
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical composition
peg
trazodone
polyethylene glycol
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12170235.1A
Other languages
German (de)
French (fr)
Other versions
EP2494955A3 (en
EP2494955A2 (en
Inventor
Marcello Marchetti
Francesca Mariotti
Lorella Ragni
Paolo Scarpetti
Mauro Valenti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angelini Acraf SpA
Original Assignee
Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco ACRAF SpA filed Critical Aziende Chimiche Riunite Angelini Francesco ACRAF SpA
Priority to SI200831393T priority Critical patent/SI2494955T1/en
Priority to PL12170235T priority patent/PL2494955T3/en
Publication of EP2494955A2 publication Critical patent/EP2494955A2/en
Publication of EP2494955A3 publication Critical patent/EP2494955A3/en
Application granted granted Critical
Publication of EP2494955B1 publication Critical patent/EP2494955B1/en
Priority to HRP20150349TT priority patent/HRP20150349T1/en
Priority to CY20151100342T priority patent/CY1116189T1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to a stable liquid pharmaceutical composition based on trazodone.
  • the invention relates to a stable liquid pharmaceutical composition based on trazodone in which the pH ranges from 5.0 to 6.0.
  • Trazodone or 2-[3-[4-(3-chlorophenyl)-1-piperazinylpropyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one, is an antidepressant which, though having a significant effect on the serotonin receptors, is neither a psychostimulant, nor a MAO inhibitor, nor a tricyclic antidepressant. Furthermore, trazodone possesses analgesic properties.
  • Trazodone alleviates the characteristic symptoms of depression, in particular anxiety, somatization, psychomotor retardation, hypochondria, mood swings, irritability, insomnia, apathy, feeling of fatigue and lack of energy, depressed mood.
  • Trazodone has also proved effective in controlling pronounced essential tremor, probably on account of its serotoninergic activity.
  • trazodone has proved useful in the treatment of symptoms of withdrawal from cocaine, benzodiazepines and alcohol.
  • trazodone is administered by the oral route as hydrochloride at initial doses of 100-150 mg per day, which can be increased by 50 mg every 3-4 days up to 300-400 mg per day.
  • the daily dosage can be divided during the day to correspond to meal times or can be administered as a single dose at bedtime. In severe depression, up to 800 mg per day can be administered.
  • Trazodone is preferably used medically in the form of a pharmaceutically acceptable salt of acid addition, and more preferably in the form of the hydrochloride.
  • the pH of a 1% (w/v) aqueous solution of trazodone hydrochloride is approx. 3.90.
  • oral pharmaceutical forms that are currently available commercially are either solid or liquid.
  • the solid pharmaceutical forms are also available as immediate-release or modified-release tablets.
  • liquid pharmaceutical forms for administration as oral drops, have the advantage that they permit greater modularity and personalization of the therapeutic dose.
  • liquid formulations for oral use (drops, syrup) or parenteral use (vials for injection), with concentrations of trazodone hydrochloride equal to approx. 1% (w/v), are being marketed.
  • a liquid pharmaceutical composition for oral use that is widely used at present has a maximum concentration of trazodone hydrochloride of 2.5% (w/v), it contains ethanol and glycerol as cosolvents, and its pH is in the range from 4.3 to 4.7.
  • this liquid pharmaceutical composition has certain disadvantages.
  • a first disadvantage is the low concentration of trazodone, so that the therapeutic dosages required involve counting a large number of drops.
  • a second disadvantage is that trazodone is incompatible with the consumption of ethanol. Therefore it would be preferable to avoid the use of ethanol as cosolvent, even if the amount taken by the patient with the aforesaid liquid pharmaceutical composition for oral use is at present almost negligible.
  • a third disadvantage is that its physical appearance changes over time, with the solution turning yellow, owing to the formation, primarily by an oxidative mechanism, of degradation products of trazodone hydrochloride.
  • stable composition means a solution of trazodone hydrochloride that does not give rise to a precipitate after 30 days of storage at a temperature of 4°C and in which the individual degradation products of trazodone hydrochloride do not exceed 0.2% after 3 months at 40oC.
  • a liquid pharmaceutical composition comprising an aqueous solution of a pharmaceutically acceptable salt of acid addition of trazodone in which the pH value is between 5.0 and 6.0 and which contains at least two cosolvents selected from the group consisting of glycols and polyglycols as in claim 1.
  • the salt of acid addition of trazodone is the hydrochloride.
  • the pH value is between 5.0 and 5.5.
  • the concentration of trazodone hydrochloride in said liquid pharmaceutical composition is preferably between 1% and 15% (w/v), more preferably between 3% and 10% (w/v), and even more preferably between 4% and 8% (w/v).
  • the concentration of trazodone hydrochloride in said liquid pharmaceutical composition is approx. 6% (w/v).
  • solubility of trazodone hydrochloride in the presence of mixtures of cosolvents according to the present invention can reach concentration levels of the order of 10-15%.
  • the total amount of cosolvents according to the present invention is in the range from 20 to 90% (w/v).
  • said total amount is in the range from 30 to 85% (w/v) and, more preferably, from 40 to 80% (w/v),
  • the liquid pharmaceutical composition of trazodone hydrochloride of the present invention comprises two cosolvents, each independently in an amount in the range from 5% to 50% (w/v), preferably from 15% to 45% (w/v).
  • liquid pharmaceutical composition of trazodone hydrochloride of the present invention comprises three cosolvents, each independently in an amount in the range from 5% to 40% (w/v), preferably from 10% to 30% (w/v).
  • the effect of the mixture of two or more cosolvents according to the present invention is even more surprising in view of the fact that none of the cosolvents tested alone was able to provide a stable composition of trazodone hydrochloride at 6% (w/v).
  • the combination of two or more cosolvents had an unexpected synergistic effect on the solubility of trazodone hydrochloride.
  • liquid pharmaceutical composition of trazodone hydrochloride according to the present invention is administered by the oral route, but it can also be administered by other routes, for example parenterally.
  • liquid pharmaceutical composition of trazodone hydrochloride according to the present invention can be prepared in various pharmaceutical forms, such as, for example in the form of aqueous solution for administration as drops, in the form of syrup, or in the form of aqueous solution for injectable vials.
  • liquid pharmaceutical composition of trazodone hydrochloride of the present invention is dispensed in the form of drops.
  • the pH is between 5.0 and 5.5.
  • the glycol used advantageously in the present invention is propylene glycol.
  • the polyglycols used in the present invention are: polyethylene glycol 200 (PEG 200), polyethylene glycol 300 (PEG 300), polyethylene glycol 400 (PEG 400), polyethylene glycol 600 (PEG 600), polyethylene glycol 1000 (PEG 1000), polyethylene glycol 1500 (PEG 1500), polyethylene glycol 3000 (PEG 3000), polyethylene glycol 3350 (PEG 3350), polyethylene glycol 4000 (PEG 4000), and polyethylene glycol 6000 (PEG 6000).
  • Typical examples of mixtures of glycols and polyglycols according to the present invention are: propylene glycol + PEG 200, propylene glycol + PEG 400, propylene glycol + PEG 6000, propylene glycol + PEG 200 + PEG 6000, propylene glycol + PEG 400 + PEG 6000, PEG 200 + PEG 6000, and PEG 400 + PEG 6000.
  • the liquid pharmaceutical composition of trazodone hydrochloride of the present invention comprises an antioxidant for preventing oxidative degradation of trazodone, regarded as the main cause of yellowing of the known solutions.
  • the antioxidant is selected from the group comprising vitamin C and its salts, vitamin E, gallic acid and its derivatives, such as propyl gallate, malic acid, sulphite of sodium or of potassium, bisulphite of sodium or of potassium, metabisulphite of sodium or of potassium, butylated hydroxyanisole (BHA), and butylated hydroxytoluene (BHT).
  • the antioxidant is selected from the group comprising gallic acid and its derivatives.
  • the liquid pharmaceutical composition of trazodone hydrochloride of the present invention also comprises other ingredients commonly used in the preparation of pharmaceutical formulations, such as, for example, chelating agents, buffers, pH correctors, surfactants, cyclodextrins, colorants, sweeteners, preservatives and the like.
  • other ingredients commonly used in the preparation of pharmaceutical formulations such as, for example, chelating agents, buffers, pH correctors, surfactants, cyclodextrins, colorants, sweeteners, preservatives and the like.
  • the chelating agent is selected from the group comprising ethylenediamine tetraacetic acid (EDTA) and its salts, such as, for example, dipotassium ethylenediamine tetraacetate, calcium disodium ethylenediamine tetraacetate, tetrasodium ethylenediamine tetraacetate, trisodium ethylenediamine tetraacetate.
  • EDTA ethylenediamine tetraacetic acid
  • its salts such as, for example, dipotassium ethylenediamine tetraacetate, calcium disodium ethylenediamine tetraacetate, tetrasodium ethylenediamine tetraacetate, trisodium ethylenediamine tetraacetate.
  • liquid pharmaceutical composition of the present invention is prepared by conventional techniques that comprise dissolution, mixing, filtration and the like.
  • liquid pharmaceutical composition of the present invention is prepared in a nitrogen gas atmosphere by bubbling gaseous nitrogen in the solution under preparation.
  • the solution was then cooled to 25°C, maintaining constant magnetic stirring at a speed of 500 rev/min.
  • Example 1 The procedure of Example 1 was repeated, replacing the propylene glycol with an equal amount of PEG 400.
  • the solution was then cooled to 25°C, maintaining constant magnetic stirring at a speed of 500 rev/min.
  • D and E were put in a 250-ml beaker and were dissolved at 25oC, with magnetic stirring at a speed of 500 rev/min, in 50% of F.
  • D was put in a 250-ml beaker and was dissolved at 25°C and with magnetic stirring at a speed of 500 rev/min in B.
  • E was dissolved at 25°C with magnetic stirring at a speed of 500 rev/min in 50% of F.
  • D was put in a 250-ml beaker and was dissolved at 25oC and with magnetic stirring at a speed of 500 rev/min in B and C.
  • E was dissolved separately, at 25oC and with magnetic stirring at a speed of 500 rev/min, in 50% of F.
  • D was put in a dissolver equipped with a turbine agitator and was dissolved at room temperature in B.
  • E was dissolved separately, at 25oC and with magnetic stirring at a speed of 500 rev/min, in 50% of G.
  • G was dissolved separately, at 25oC and with magnetic stirring at a speed of 500 rev/min, in 40% of H.
  • B and C were put in a 250-ml beaker and were dissolved at 25oC with magnetic stirring at a speed of 500 rev/min in 90% of D. Then, still at 25oC and with magnetic stirring at a speed of 500 rev/min, A was added, stirring until it had dissolved completely.
  • G was put in a 250-ml beaker and was dissolved at 25oC with magnetic stirring at a speed of 500 rev/min in C.
  • D was dissolved separately in a 150-ml beaker, at 25oC and with magnetic stirring at a speed of 300-400 rev/min, in 50% of H.
  • examples 1 to 10 were stored at room temperature for 30 days and in a refrigerator at 4oC for 30 days. All the formulations proved to be stable in storage at room temperature, remaining clear and free from precipitate. Formulations 1 and 2 produced a precipitate when stored in the refrigerator at 4oC. Formulations 3 to 10 also remained stable on storage in the refrigerator, remaining clear and free from precipitate. The formulation of Example 3 was additionally stored in the refrigerator at 4oC for 4 months, and did not display formation of precipitate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Description

    Field of the invention
  • The present invention relates to a stable liquid pharmaceutical composition based on trazodone.
  • In particular, the invention relates to a stable liquid pharmaceutical composition based on trazodone in which the pH ranges from 5.0 to 6.0.
    • Prior art
  • Trazodone, or 2-[3-[4-(3-chlorophenyl)-1-piperazinylpropyl]-1,2,4-triazolo[4,3-a]pyridin-3(2H)-one, is an antidepressant which, though having a significant effect on the serotonin receptors, is neither a psychostimulant, nor a MAO inhibitor, nor a tricyclic antidepressant. Furthermore, trazodone possesses analgesic properties.
  • Trazodone alleviates the characteristic symptoms of depression, in particular anxiety, somatization, psychomotor retardation, hypochondria, mood swings, irritability, insomnia, apathy, feeling of fatigue and lack of energy, depressed mood.
  • Trazodone has also proved effective in controlling pronounced essential tremor, probably on account of its serotoninergic activity.
  • Moreover, the antidepressant and anxiolytic properties of trazodone have proved useful in the treatment of symptoms of withdrawal from cocaine, benzodiazepines and alcohol.
  • Besides the above-mentioned activities, its sleep-inducing activity is also very interesting.
  • In the treatment of depression, trazodone is administered by the oral route as hydrochloride at initial doses of 100-150 mg per day, which can be increased by 50 mg every 3-4 days up to 300-400 mg per day. The daily dosage can be divided during the day to correspond to meal times or can be administered as a single dose at bedtime. In severe depression, up to 800 mg per day can be administered.
  • Trazodone is preferably used medically in the form of a pharmaceutically acceptable salt of acid addition, and more preferably in the form of the hydrochloride.
  • The solubility of trazodone hydrochloride at room temperature in the commonest solvents is as follows:
    • water
    : 1.8 g/100 ml
    95% ethanol
    : 1.6 g/100 ml
    methanol
    : 2.5 g/100 ml
    chloroform
    : 3.6 g/100 ml
    benzene
    : practically insoluble
    ethyl ether
    : practically insoluble
    octanol
    : less than 0.1 g/100 ml
    olive oil
    : less than 0.1 g/100 ml
  • The pH of a 1% (w/v) aqueous solution of trazodone hydrochloride is approx. 3.90.
  • In water, the solubility of trazodone hydrochloride increases with increase in acidity of the aqueous medium. However, as the acidity of the aqueous medium increases, the degradation of trazodone hydrochloride also increases.
  • This degradation appears to take place by an oxidative mechanism via the formation of an N-oxide, namely 4-(3- chlorophenyl)-1-[3-(3-oxa-2,3-dihydro-1,2,4-triazolo[4,3-α]pyridin-2-yl)-propyl]-piperazine N1-oxide.
  • The oral pharmaceutical forms that are currently available commercially are either solid or liquid.
  • The solid pharmaceutical forms are also available as immediate-release or modified-release tablets.
  • The liquid pharmaceutical forms, for administration as oral drops, have the advantage that they permit greater modularity and personalization of the therapeutic dose.
  • Various liquid formulations, for oral use (drops, syrup) or parenteral use (vials for injection), with concentrations of trazodone hydrochloride equal to approx. 1% (w/v), are being marketed. A liquid pharmaceutical composition for oral use that is widely used at present has a maximum concentration of trazodone hydrochloride of 2.5% (w/v), it contains ethanol and glycerol as cosolvents, and its pH is in the range from 4.3 to 4.7.
  • However, this liquid pharmaceutical composition has certain disadvantages.
  • A first disadvantage is the low concentration of trazodone, so that the therapeutic dosages required involve counting a large number of drops.
  • A second disadvantage is that trazodone is incompatible with the consumption of ethanol. Therefore it would be preferable to avoid the use of ethanol as cosolvent, even if the amount taken by the patient with the aforesaid liquid pharmaceutical composition for oral use is at present almost negligible.
  • A third disadvantage is that its physical appearance changes over time, with the solution turning yellow, owing to the formation, primarily by an oxidative mechanism, of degradation products of trazodone hydrochloride.
  • Therefore there is still a great need for a liquid pharmaceutical composition of trazodone hydrochloride for oral administration in which an amount of trazodone hydrochloride greater than or equal to 1% (w/v) can be dissolved stably, does not contain ethanol as solvent or cosolvent, and does not turn yellow over time.
    • Definitions
  • In the present description and in the claims, the expression "stable composition" means a solution of trazodone hydrochloride that does not give rise to a precipitate after 30 days of storage at a temperature of 4°C and in which the individual degradation products of trazodone hydrochloride do not exceed 0.2% after 3 months at 40ºC.
    • Description of the invention
  • It was found, surprisingly, that this aim is achieved with a liquid pharmaceutical composition comprising an aqueous solution of a pharmaceutically acceptable salt of acid addition of trazodone in which the pH value is between 5.0 and 6.0 and which contains at least two cosolvents selected from the group consisting of glycols and polyglycols as in claim 1. Preferably, the salt of acid addition of trazodone is the hydrochloride. Preferably, the pH value is between 5.0 and 5.5.
  • The concentration of trazodone hydrochloride in said liquid pharmaceutical composition is preferably between 1% and 15% (w/v), more preferably between 3% and 10% (w/v), and even more preferably between 4% and 8% (w/v). Advantageously, the concentration of trazodone hydrochloride in said liquid pharmaceutical composition is approx. 6% (w/v).
  • Surprisingly, it was found that the use of at least two cosolvents selected from the group comprising glycols and polyglycols makes it possible to obtain a stable liquid composition of trazodone hydrochloride at concentrations above 3% (w/v), and preferably even above 6% (w/v).
  • The solubility of trazodone hydrochloride in the presence of mixtures of cosolvents according to the present invention can reach concentration levels of the order of 10-15%.
  • Generally, the total amount of cosolvents according to the present invention is in the range from 20 to 90% (w/v). Preferably, said total amount is in the range from 30 to 85% (w/v) and, more preferably, from 40 to 80% (w/v),
  • Preferably, the liquid pharmaceutical composition of trazodone hydrochloride of the present invention comprises two cosolvents, each independently in an amount in the range from 5% to 50% (w/v), preferably from 15% to 45% (w/v).
  • Alternatively, the liquid pharmaceutical composition of trazodone hydrochloride of the present invention comprises three cosolvents, each independently in an amount in the range from 5% to 40% (w/v), preferably from 10% to 30% (w/v).
  • The effect of the mixture of two or more cosolvents according to the present invention is all the more surprising if we bear in mind that, as already mentioned, the solubility of trazodone hydrochloride decreases with decrease in acidity of the aqueous medium. Thus, the possibility of increasing the concentration of trazodone hydrochloride from 2.5% to 6% (w/v), with change from pH 4.3-4.7 to pH 5.0-5.5, was completely unexpected. The increase is in fact 140%.
  • Moreover, the effect of the mixture of two or more cosolvents according to the present invention is even more surprising in view of the fact that none of the cosolvents tested alone was able to provide a stable composition of trazodone hydrochloride at 6% (w/v). Thus, the combination of two or more cosolvents had an unexpected synergistic effect on the solubility of trazodone hydrochloride.
  • Generally, the liquid pharmaceutical composition of trazodone hydrochloride according to the present invention is administered by the oral route, but it can also be administered by other routes, for example parenterally.
  • The liquid pharmaceutical composition of trazodone hydrochloride according to the present invention can be prepared in various pharmaceutical forms, such as, for example in the form of aqueous solution for administration as drops, in the form of syrup, or in the form of aqueous solution for injectable vials.
  • Typically, the liquid pharmaceutical composition of trazodone hydrochloride of the present invention is dispensed in the form of drops.
  • In a preferred embodiment of the present invention the pH is between 5.0 and 5.5.
  • The glycol used advantageously in the present invention is propylene glycol.
  • The polyglycols used in the present invention are: polyethylene glycol 200 (PEG 200), polyethylene glycol 300 (PEG 300), polyethylene glycol 400 (PEG 400), polyethylene glycol 600 (PEG 600), polyethylene glycol 1000 (PEG 1000), polyethylene glycol 1500 (PEG 1500), polyethylene glycol 3000 (PEG 3000), polyethylene glycol 3350 (PEG 3350), polyethylene glycol 4000 (PEG 4000), and polyethylene glycol 6000 (PEG 6000).
  • Typical examples of mixtures of glycols and polyglycols according to the present invention are: propylene glycol + PEG 200, propylene glycol + PEG 400, propylene glycol + PEG 6000, propylene glycol + PEG 200 + PEG 6000, propylene glycol + PEG 400 + PEG 6000, PEG 200 + PEG 6000, and PEG 400 + PEG 6000.
  • Advantageously, the liquid pharmaceutical composition of trazodone hydrochloride of the present invention comprises an antioxidant for preventing oxidative degradation of trazodone, regarded as the main cause of yellowing of the known solutions.
  • Advantageously, the antioxidant is selected from the group comprising vitamin C and its salts, vitamin E, gallic acid and its derivatives, such as propyl gallate, malic acid, sulphite of sodium or of potassium, bisulphite of sodium or of potassium, metabisulphite of sodium or of potassium, butylated hydroxyanisole (BHA), and butylated hydroxytoluene (BHT). Preferably, the antioxidant is selected from the group comprising gallic acid and its derivatives.
  • Preferably, the liquid pharmaceutical composition of trazodone hydrochloride of the present invention also comprises other ingredients commonly used in the preparation of pharmaceutical formulations, such as, for example, chelating agents, buffers, pH correctors, surfactants, cyclodextrins, colorants, sweeteners, preservatives and the like.
  • Preferably, the chelating agent is selected from the group comprising ethylenediamine tetraacetic acid (EDTA) and its salts, such as, for example, dipotassium ethylenediamine tetraacetate, calcium disodium ethylenediamine tetraacetate, tetrasodium ethylenediamine tetraacetate, trisodium ethylenediamine tetraacetate.
  • The liquid pharmaceutical composition of the present invention is prepared by conventional techniques that comprise dissolution, mixing, filtration and the like.
  • Advantageously, the liquid pharmaceutical composition of the present invention is prepared in a nitrogen gas atmosphere by bubbling gaseous nitrogen in the solution under preparation.
  • The following examples will illustrate the invention, though without limiting it.
    • EXAMPLE 1
  • (Comparative)
    Drops
    A. Trazodone hydrochloride : 6 g
    B. Propylene glycol : 40 g
    C. Purified water : qsf. 100 ml
  • B and 90% of C were put in a 250-ml beaker and the solution was heated to 50ºC with magnetic stirring at a speed of 500 rev/min.
  • When the solution reached 50°C, A and the remainder of C were added, still with magnetic stirring at 500 rev/min,
  • After such additions, the pH was corrected from 3.38 to 5.20 with approx. 18 g of 1% NaOH aqueous solution.
  • The solution was then cooled to 25°C, maintaining constant magnetic stirring at a speed of 500 rev/min.
    • EXAMPLE 2 (Comparative)
  • The procedure of Example 1 was repeated, replacing the propylene glycol with an equal amount of PEG 400.
    • EXAMPLE 3
  • (Invention)
    Drops
    A. Trazodone hydrochloride : 6 g
    B. Propylene glycol : 20 g
    C. PEG 400 : 30 g
    D. Purified water : qsf. 100 ml
  • B, C and 90% of D were put in a 250-ml beaker and the solution was heated to 50ºC with magnetic stirring at a speed of 500 rev/min.
  • When the solution reached 50°C, A and the remainder of D were added, still with magnetic stirring at 500 rev/min.
  • After addition, the pH was corrected from 4.50 to 5.20 with approx. 18 g of 1% NaOH aqueous solution.
  • The solution was then cooled to 25°C, maintaining constant magnetic stirring at a speed of 500 rev/min.
    • EXAMPLE 4
  • (Invention)
    Drops
    A. Trazodone hydrochloride : 6 g
    B. Propylene glycol : 30 g
    C. PEG 400 : 35 g
    D. Sodium metabisulphite : 0.1 g
    E. Disodium EDTA : 0.1 g
    F. Purified water : qsf. 100 ml
  • D and E were put in a 250-ml beaker and were dissolved at 25ºC, with magnetic stirring at a speed of 500 rev/min, in 50% of F.
  • Then, still at 25°C and with magnetic stirring at a speed of 500 rev/min, B, C and 45% of F were added.
  • Finally, still at 25°C and with magnetic stirring at a speed of 500 rev/min, A and the remaining 5% of F were added and the pH was corrected from 4.80 to 5.20 with approx. 15 g of 1% NaOH aqueous solution.
    • EXAMPLE 5
  • (Invention)
    Drops
    A. Trazodone hydrochloride : 6 g
    B. Propylene glycol : 30 g
    C. PEG 400 : 35 g
    D. Propyl gallate : 0.1 g
    E. Disodium EDTA : 0.1 g
    F. Purified water : qsf. 100 ml
  • D was put in a 250-ml beaker and was dissolved at 25°C and with magnetic stirring at a speed of 500 rev/min in B.
  • E was dissolved at 25°C with magnetic stirring at a speed of 500 rev/min in 50% of F.
  • The two solutions were combined, and C and 45% of F were added, at 25ºC and with magnetic stirring at a speed of 400-500 rev/min.
  • Finally, A and the remaining 5% of F were added, at 25ºC and with magnetic stirring at a speed of 500 rev/min, and the pH was adjusted from 4.66 to 5.20 with 15 g of 1 % NaOH aqueous solution.
    • EXAMPLE 6
  • (Invention)
    Drops
    A. Trazodone hydrochloride : 6 g
    B. Propylene glycol : 40 g
    C. PEG 6000 : 5 g
    D. Propyl gallate : 0.1 g
    E. Disodium EDTA : 0.1 g
    F. Purified water : qsf. 100 ml
  • D was put in a 250-ml beaker and was dissolved at 25ºC and with magnetic stirring at a speed of 500 rev/min in B and C.
  • E was dissolved separately, at 25ºC and with magnetic stirring at a speed of 500 rev/min, in 50% of F.
  • The two solutions were combined, and 45% of F was added, at 25ºC and with magnetic stirring at a speed of 500 rev/min.
  • Finally, A and the remaining 5% of F were added, at 25ºC and with magnetic stirring at a speed of 500 rev/min, and the pH was adjusted from 4.25 to 5.20 with approx. 18 g of 1% NaOH aqueous solution.
    • Example 7
  • (Invention)
    Drops
    A. Trazodone hydrochloride : 6 g
    B. Propylene glycol : 30 g
    C. PEG 400 : 35 g
    D. Propyl gallate : 0.1 g
    E. Disodium EDTA : 0.1 g
    F. Sucralose : 0.05 g
    G. Purified water : qsf. 100 ml
  • D was put in a dissolver equipped with a turbine agitator and was dissolved at room temperature in B.
  • E was dissolved separately, at 25ºC and with magnetic stirring at a speed of 500 rev/min, in 50% of G.
  • The two solutions were combined, and C, F and 45% of G were added, at 25ºC and with magnetic stirring at a speed of 400-500 rev/min.
  • Finally, A and the remaining 5% of G were added, at 25ºC and with magnetic stirring at a speed of 500 rev/min, and the pH was adjusted from 4.61 to 5.20 with approx. 18 g of 1% NaOH aqueous solution.
    • EXAMPLE 8
  • (Invention)
    Syrup
    A. Trazodone hydrochloride : 1 g
    B. PEG 400 : 20 g
    C. Propylene glycol : 10 g
    D. PEG 6000 : 10 g
    E. Sodium saccharin : 0.08 g
    F. Aroma : 0.1 g
    G. Benzoic acid : 0.1 g
    H. Purified water : qsf. 100 ml
  • B, C and D were put in a 250-ml beaker and were dissolved at 25ºC and with magnetic stirring at a speed of 500 rev/min in 60% of H. Then, still at 25ºC and with magnetic stirring at a speed of 500 rev/min, A was added.
  • G was dissolved separately, at 25ºC and with magnetic stirring at a speed of 500 rev/min, in 40% of H.
  • The two solutions were combined, and E and F were added, still at a temperature of 25ºC and with magnetic stirring at a speed of 500 rev/min.
  • Then the pH was corrected from 4.35 to 5.40 with approx. 1 g of 10% NaOH aqueous solution.
    • EXAMPLE 9
  • (Invention)
    Aqueous solution for injectable vials
    A. Trazodone hydrochloride : 1 g
    B. PEG 400 : 30 g
    C. Propylene glycol : 10 g
    D. Purified water : qsf. 100 ml
  • B and C were put in a 250-ml beaker and were dissolved at 25ºC with magnetic stirring at a speed of 500 rev/min in 90% of D. Then, still at 25ºC and with magnetic stirring at a speed of 500 rev/min, A was added, stirring until it had dissolved completely.
  • Finally, the remaining 10% of D was added and the pH was corrected from 4.60 to 5.20 with approx. 1 g of 10% NaOH aqueous solution.
    • EXAMPLE 10
  • (Invention)
    Drops
    A. Trazodone hydrochloride : 6 g
    B. PEG 400 : 35 g
    C. Propylene glycol : 30 g
    D. Disodium EDTA : 0.1 g
    E. Sucralose : 0.15 g
    F. Anhydrous citric acid : 0.5 g
    G. Propyl gallate : 0.1 g
    H. Purified water : qsf. 100 ml
  • G was put in a 250-ml beaker and was dissolved at 25ºC with magnetic stirring at a speed of 500 rev/min in C.
  • D was dissolved separately in a 150-ml beaker, at 25ºC and with magnetic stirring at a speed of 300-400 rev/min, in 50% of H.
  • The two solutions were combined, and A, B, E and F were added, still at 25ºC and with magnetic stirring at a speed of 500 rev/min.
  • Finally, the remaining 50% of H was added and the pH was corrected from 4.80 to 5.20 with approx. 15 g of 1% NaOH aqueous solution.
    • EXAMPLE 11 (Stability tests)
  • The formulations in examples 1 to 10 were stored at room temperature for 30 days and in a refrigerator at 4ºC for 30 days. All the formulations proved to be stable in storage at room temperature, remaining clear and free from precipitate. Formulations 1 and 2 produced a precipitate when stored in the refrigerator at 4ºC. Formulations 3 to 10 also remained stable on storage in the refrigerator, remaining clear and free from precipitate. The formulation of Example 3 was additionally stored in the refrigerator at 4ºC for 4 months, and did not display formation of precipitate.
  • The formulations of examples 3, 5, 6 and 7 were stored at 40ºC and 75% relative humidity, for a variable length of time as shown in Tables 1 and 2 below.
  • At the end of each period of storage, the formulations were submitted to pharmaceutical analyses, to verify their appearance and presence of any precipitate, and chemical analyses, for verifying presence of trazodone degradation products. The results are presented in the same Tables 1 and 2. TABLE 1
    Pharmaceutical analyses
    Storage at 40ºC and 75% RH for:
    1 month 2 months 3 months 4 months
    Example 3 - Solution slightly yellowed No precipitate pH 5.10 Solution slightly yellowed No precipitate Solution yellowed pH 5.04
    Example 5 - Clear, colourless solution No precipitate - Clear, colourless solution No precipitate
    Example 6 Clear, colourless solution No precipitate - - -
    Example 7 Clear, colourless solution No precipitate pH 5.27 - Clear, colourless solution No precipitate pH 5.10
    TABLE 2
    Chemical analyses
    Storage at 40ºC and 75% RH for:
    1 month 2 months 3 months 4 months
    Example 3 - - N-oxide 0.11% -
    Others 0.09%
    Example 5 N-oxide 0.05% N-oxide 0.05% - N-oxide 0.05%
    Others 0.01 % Others 0.01 % Others 0.02%
    Example 7 N-oxide 0.03% - N-oxide 0.04%
    Others <0.02% Others <0.02%

Claims (13)

  1. Stable liquid pharmaceutical composition comprising an aqueous solution of a pharmaceutically acceptable salt of acid addition of trazodone, characterized in that said pharmaceutical composition has a pH value between 5.0 and 6.0, and comprises at least two cosolvents selected from the group consisting of propylene glycol, polyethylene glycol 200 (PEG 200), polyethylene glycol 300 (PEG 300), polyethylene glycol 400 (PEG 400), polyethylene glycol 600 (PEG 600), polyethylene glycol 1000 (PEG 1000), polyethylene glycol 1500 (PEG 1500), polyethylene glycol 3000 (PEG 3000); polyethylene glycol 3350 (PEG 3350), polyethylene glycol 4000 (PEG 4000), and polyethylene glycol 6000 (PEG 6000).
  2. Pharmaceutical composition according to Claim 1, characterized in that it has a pH value between 5.0 and 5.5.
  3. Pharmaceutical composition according to any one of the preceding claims, characterized in that it comprises a total amount of said cosolvents in the range from 20% to 90% (w/v).
  4. Pharmaceutical composition according to Claim 3, characterized in that it comprises a total amount of said cosolvents in the range from 30% to 85% (w/v).
  5. Pharmaceutical composition according to Claim 4, characterized in that it comprises a total amount of said cosolvents in the range from 40% to 80% (w/v).
  6. Pharmaceutical composition according to Claim 1, characterized in that it comprises two cosolvents, each independently in an amount in the range from 5% to 50% (w/v), but in total amount not greater than 90% (w/v).
  7. Pharmaceutical composition according to Claim 1, characterized in that it comprises three cosolvents, each independently in an amount in the range from 5% to 40% (w/v), but in total amount not greater than 90% (w/v).
  8. Pharmaceutical composition according to any one of the preceding claims, characterized in that it comprises an amount of said pharmaceutically acceptable salt of acid addition of trazodone between 1% and 15% (w/v).
  9. Pharmaceutical composition according to Claim 8, characterized in that it comprises an amount of said pharmaceutically acceptable salt of acid addition of trazodone between 3 and 10% (w/v).
  10. Pharmaceutical composition according to Claim 8, characterized in that it comprises an amount of said pharmaceutically acceptable salt of acid addition of trazodone between 4% and 8% (w/v).
  11. Pharmaceutical composition according to any one of the preceding claims, characterized in that said pharmaceutically acceptable salt of acid addition of trazodone is trazodone hydrochloride.
  12. Pharmaceutical composition according to any one of the preceding claims, characterized in that it comprises at least one antioxidant.
  13. Pharmaceutical composition according to any one of the preceding claims, characterized in that it comprises at least one additive selected from the group comprising chelating agents, buffers, pH correctors, surfactants, cyclodextrins, colorants, sweeteners, and preservatives.
EP12170235.1A 2007-07-31 2008-07-22 Stable liquid pharmaceutical composition based on trazodone Active EP2494955B1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
SI200831393T SI2494955T1 (en) 2007-07-31 2008-07-22 Stable liquid pharmaceutical composition based on trazodone
PL12170235T PL2494955T3 (en) 2007-07-31 2008-07-22 Stable liquid pharmaceutical composition based on trazodone
HRP20150349TT HRP20150349T1 (en) 2007-07-31 2015-03-27 Stable liquid pharmaceutical composition based on trazodone
CY20151100342T CY1116189T1 (en) 2007-07-31 2015-04-09 TREASURY-based STABLE LIQUID PHARMACEUTICAL COMPOSITION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001573A ITMI20071573A1 (en) 2007-07-31 2007-07-31 LIQUID PHARMACEUTICAL COMPOSITION STABLE ON THE BASIS OF TRAZODONE
EP08775278A EP2182920B1 (en) 2007-07-31 2008-07-22 Stable liquid pharmaceutical composition based on trazodone

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP08775278.8 Division 2008-07-22
EP08775278A Division EP2182920B1 (en) 2007-07-31 2008-07-22 Stable liquid pharmaceutical composition based on trazodone

Publications (3)

Publication Number Publication Date
EP2494955A2 EP2494955A2 (en) 2012-09-05
EP2494955A3 EP2494955A3 (en) 2012-10-03
EP2494955B1 true EP2494955B1 (en) 2015-01-21

Family

ID=38858941

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12170235.1A Active EP2494955B1 (en) 2007-07-31 2008-07-22 Stable liquid pharmaceutical composition based on trazodone
EP08775278A Active EP2182920B1 (en) 2007-07-31 2008-07-22 Stable liquid pharmaceutical composition based on trazodone

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08775278A Active EP2182920B1 (en) 2007-07-31 2008-07-22 Stable liquid pharmaceutical composition based on trazodone

Country Status (25)

Country Link
US (1) US10292931B2 (en)
EP (2) EP2494955B1 (en)
JP (1) JP5426548B2 (en)
KR (1) KR101493370B1 (en)
CN (1) CN101784257B (en)
AR (1) AR068327A1 (en)
AU (1) AU2008281858B2 (en)
BR (1) BRPI0814658A2 (en)
CA (1) CA2692975C (en)
CY (1) CY1116189T1 (en)
DK (2) DK2182920T3 (en)
EA (1) EA016822B1 (en)
ES (2) ES2531241T3 (en)
GE (1) GEP20125525B (en)
HK (2) HK1176280A1 (en)
HR (1) HRP20150349T1 (en)
IL (1) IL203167A (en)
IT (1) ITMI20071573A1 (en)
MX (1) MX2010001092A (en)
PL (2) PL2494955T3 (en)
PT (2) PT2182920E (en)
SG (1) SG183659A1 (en)
SI (2) SI2494955T1 (en)
UA (1) UA102376C2 (en)
WO (1) WO2009016069A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20071603A1 (en) 2007-08-03 2009-02-04 Acraf TRAZODONE AND CHLORIDATED TRAZODONE IN PURIFIED FORM
WO2012072665A1 (en) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors
RU2706700C1 (en) * 2019-09-24 2019-11-20 Общество с ограниченной ответственностью "Научно-производственная компания "СКиФФ" Pharmaceutical composition for correcting behavior of cats and dogs in stress situations
CN114615983A (en) * 2019-09-26 2022-06-10 安杰利尼股份公司 Pediatric trazodone compositions and methods of treatment thereof
CN111568861A (en) * 2020-05-25 2020-08-25 河北科星药业有限公司 Bromhexine hydrochloride oral liquid for livestock and poultry as well as preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4154832A (en) * 1974-08-26 1979-05-15 Bruno Silvestrini Novel treatment for acute organic cerebral syndromes (strokes)
IT1233412B (en) * 1987-12-02 1992-03-30 Acraf USE OF TRAZODONE
RU2224523C2 (en) 1998-07-24 2004-02-27 Сео Хонг Ю Bile acid-containing aqueous solution and method for its preparing
AU2003903597A0 (en) 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
ITMI20071603A1 (en) 2007-08-03 2009-02-04 Acraf TRAZODONE AND CHLORIDATED TRAZODONE IN PURIFIED FORM

Also Published As

Publication number Publication date
EP2182920B1 (en) 2012-12-26
SG183659A1 (en) 2012-09-27
HRP20150349T1 (en) 2015-05-22
PT2494955E (en) 2015-03-04
AU2008281858A1 (en) 2009-02-05
EP2494955A3 (en) 2012-10-03
KR101493370B1 (en) 2015-02-13
DK2182920T3 (en) 2013-03-04
WO2009016069A3 (en) 2009-03-19
PT2182920E (en) 2013-03-07
PL2494955T3 (en) 2015-06-30
WO2009016069A2 (en) 2009-02-05
EP2494955A2 (en) 2012-09-05
JP5426548B2 (en) 2014-02-26
CN101784257B (en) 2012-11-28
KR20100038112A (en) 2010-04-12
CA2692975C (en) 2016-01-12
SI2182920T1 (en) 2013-04-30
IL203167A (en) 2017-08-31
WO2009016069A4 (en) 2009-05-14
HK1138207A1 (en) 2010-08-20
PL2182920T3 (en) 2013-05-31
BRPI0814658A2 (en) 2015-02-18
CY1116189T1 (en) 2017-02-08
US10292931B2 (en) 2019-05-21
AU2008281858B2 (en) 2014-02-27
US20100256159A1 (en) 2010-10-07
DK2494955T3 (en) 2015-04-13
ITMI20071573A1 (en) 2009-02-01
EA201070194A1 (en) 2010-06-30
MX2010001092A (en) 2010-03-01
EA016822B1 (en) 2012-07-30
ES2531241T3 (en) 2015-03-12
SI2494955T1 (en) 2015-04-30
CA2692975A1 (en) 2009-02-05
JP2010534703A (en) 2010-11-11
GEP20125525B (en) 2012-05-25
AR068327A1 (en) 2009-11-11
EP2182920A2 (en) 2010-05-12
ES2399569T3 (en) 2013-04-02
HK1176280A1 (en) 2013-07-26
UA102376C2 (en) 2013-07-10
CN101784257A (en) 2010-07-21

Similar Documents

Publication Publication Date Title
FI116510B (en) Aqueous risperidone compositions
EP2494955B1 (en) Stable liquid pharmaceutical composition based on trazodone
WO2009111057A4 (en) Fulvestrant formulations
TWI280880B (en) Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances
JP2014503542A (en) An aqueous solution of ambroxol
ITMI991697A1 (en) PARACETAMOL-BASED LIQUID PHARMACEUTICAL COMPOSITION
CN104873461A (en) Preparation method for lamotrigine oral solution
CA3002786C (en) Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-.beta.1 gene
Taylor et al. Pharmacokinetics and efficacy of high‐dose metoclopramide given by continuous infusion for the control of cytotoxic drug‐induced vomiting.
US3733410A (en) Elixirs with acid addition salts of therapeutically active organic bases as active substances
EP0228223A2 (en) Non-irritating suprofen solution
AU742878B2 (en) Intranasal formulation containing scopolamine and method of treating motion sickness
US6239165B1 (en) Liquid pharmaceutical formulation containing zotepine
WO2024062443A1 (en) Pharmaceutical compositions
EP1830801B1 (en) Drop preparations comprising dimetindene
US8044104B2 (en) Prostaglandin derivative-containing aqueous liquid preparation
JPH08193023A (en) Stable aqueous drug composition
MXPA00007410A (en) Liquid pharmaceutical formulation containing zotepine

Legal Events

Date Code Title Description
PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2182920

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20060101ALI20120828BHEP

Ipc: A61K 31/495 20060101ALI20120828BHEP

Ipc: A61K 9/08 20060101AFI20120828BHEP

Ipc: A61P 25/24 20060101ALI20120828BHEP

17P Request for examination filed

Effective date: 20130325

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1176280

Country of ref document: HK

17Q First examination report despatched

Effective date: 20130819

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140917

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 2182920

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20150226

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008036524

Country of ref document: DE

Effective date: 20150305

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2531241

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150312

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 708830

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150315

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

Ref country code: DE

Ref legal event code: R082

Ref document number: 602008036524

Country of ref document: DE

Representative=s name: REITSTOETTER KINZEBACH, DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20150349

Country of ref document: HR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20150409

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20150349

Country of ref document: HR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20150400707

Country of ref document: GR

Effective date: 20150421

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E010439

Country of ref document: EE

Effective date: 20150410

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20150121

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 18440

Country of ref document: SK

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1176280

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008036524

Country of ref document: DE

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E024458

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20151022

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 708830

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150121

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20150349

Country of ref document: HR

Payment date: 20190709

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20150349

Country of ref document: HR

Payment date: 20200716

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20150349

Country of ref document: HR

Payment date: 20210715

Year of fee payment: 14

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20150349

Country of ref document: HR

Payment date: 20220718

Year of fee payment: 15

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20230622

Year of fee payment: 16

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20150349

Country of ref document: HR

Payment date: 20230719

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20230623

Year of fee payment: 16

Ref country code: NL

Payment date: 20230719

Year of fee payment: 16

Ref country code: LU

Payment date: 20230719

Year of fee payment: 16

Ref country code: IS

Payment date: 20230615

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20230721

Year of fee payment: 16

Ref country code: RO

Payment date: 20230718

Year of fee payment: 16

Ref country code: NO

Payment date: 20230721

Year of fee payment: 16

Ref country code: MT

Payment date: 20230623

Year of fee payment: 16

Ref country code: MC

Payment date: 20230724

Year of fee payment: 16

Ref country code: IT

Payment date: 20230712

Year of fee payment: 16

Ref country code: IE

Payment date: 20230719

Year of fee payment: 16

Ref country code: GB

Payment date: 20230720

Year of fee payment: 16

Ref country code: FI

Payment date: 20230719

Year of fee payment: 16

Ref country code: ES

Payment date: 20230926

Year of fee payment: 16

Ref country code: EE

Payment date: 20230717

Year of fee payment: 16

Ref country code: CZ

Payment date: 20230717

Year of fee payment: 16

Ref country code: CY

Payment date: 20230719

Year of fee payment: 16

Ref country code: CH

Payment date: 20230801

Year of fee payment: 16

Ref country code: BG

Payment date: 20230719

Year of fee payment: 16

Ref country code: AT

Payment date: 20230720

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20230719

Year of fee payment: 16

Ref country code: SI

Payment date: 20230713

Year of fee payment: 16

Ref country code: SE

Payment date: 20230719

Year of fee payment: 16

Ref country code: PT

Payment date: 20230713

Year of fee payment: 16

Ref country code: HU

Payment date: 20230721

Year of fee payment: 16

Ref country code: HR

Payment date: 20230719

Year of fee payment: 16

Ref country code: GR

Payment date: 20230721

Year of fee payment: 16

Ref country code: FR

Payment date: 20230725

Year of fee payment: 16

Ref country code: DK

Payment date: 20230721

Year of fee payment: 16

Ref country code: DE

Payment date: 20230719

Year of fee payment: 16

Ref country code: BE

Payment date: 20230719

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LV

Payment date: 20230719

Year of fee payment: 16